Isoprostanes and 4-hydroxy-2-nonenal: Markers or mediators of disease? focus on rett syndrome as a model of autism spectrum disorder

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Signorini, Cinzia ^a   De Felice, Claudio ^b   Durand, Thierry ^c   Oger, Camille ^c   Galano, Jean Marie ^c   Leoncini, Silvia ^a,b   Pecorelli, Alessandra ^a,b   Valacchi, Giuseppe ^d,e   Ciccoli, Lucia ^a   Hayek, Joussef ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c CNRS   (France)

^d UNIVERSITY OF FERRARA   (Italy)

^e Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4-HYDROXY-2-NONENAL; AUTISM SPECTRUM DISORDERS; CELLULAR COMPONENTS; CLINICAL MANIFESTATION; CLINICAL SETTINGS; LIPID PEROXIDATION; PATHOPHYSIOLOGICAL; SPECIFIC OXIDATION;

DISEASES; LIPIDS; POLYUNSATURATED FATTY ACIDS;

OXIDATIVE STRESS;

4 HYDROXYNONENAL; CARBONYL DERIVATIVE; HYDROXYL GROUP; ISOPROSTANE DERIVATIVE; MALONALDEHYDE; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1; 4-HYDROXY-2-NONENAL; ALDEHYDE; BIOLOGICAL MARKER;

ARTICLE; AUTISM; CELL PROLIFERATION; CEREBROSPINAL FLUID; CHEMICAL STRUCTURE; DISEASE MARKER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID COMPOSITION; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; RETT SYNDROME; METABOLISM; REVIEW;

ALDEHYDES; BIOLOGICAL MARKERS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; ISOPROSTANES; RETT SYNDROME;

EID: 84880272443     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/343824     Document Type: Article

References (100)

1. Halliwell B., Oxidative stress and cancer: have we moved forward? Biochemical Journal 2007 401 1 1 11 2-s2.0-33846331650 10.1042/BJ20061131 (Pubitemid 46115897)
2. Ferguson L. R., Chronic inflammation and mutagenesis. Mutation Research 2010 690 1-2 3 11 2-s2.0-77955267142 10.1016/j.mrfmmm.2010.03.007
3. Halliwell B., Free radicals and antioxidants-quo vadis? Trends in Pharmacological Sciences 2011 32 3 125 130 2-s2.0-79952442409 10.1016/j.tips.2010.12.002
4. Halliwell B., Oxidative stress and neurodegeneration: where are we now? Journal of Neurochemistry 2006 97 6 1634 1658 2-s2.0-33745013111 10.1111/j.1471-4159.2006.03907.x (Pubitemid 43873658)
5. Praticò D., The neurobiology of isoprostanes and Alzheimer's disease. Biochimica et Biophysica Acta 2010 1801 8 930 933 2-s2.0-77953251572 10.1016/j.bbalip.2010.01.009
6. Aluise C. D., Robinson R. A. S., Cai J., Pierce W. M., Markesbery W. R., Butterfield D. A., Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical alzheimer's disease: insights into memory loss in MCI. Journal of Alzheimer's Disease 2011 23 2 257 269 2-s2.0-79951560784 10.3233/JAD-2010-101083
7. Halliwell B., Free Radicals in Biology and Medicine 2007 4th Oxford, UK Oxford University Press
8. Brazil J. C., Louis N. A., Parkos C. A., The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory Bowel disease. Inflammatory Bowel Diseases 2013 19 7 1556 1565 10.1097/MIB.0b013e318281f54e
9. Halliwell B., Free radicals and antioxidants: updating a personal view. Nutrition Reviews 2012 70 5 257 265 2-s2.0-84860331697 10.1111/j.1753-4887.2012. 00476.x
10. Bannenberg G. L., Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators. The Scientific World Journal 2010 10 676 712 2-s2.0-77952897873 10.1100/tsw.2010.57
11. Serhan C. N., Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? American Journal of Pathology 2010 177 4 1576 1591 2-s2.0-77957325778 10.2353/ajpath.2010.100322
12. Esterbauer H., Schaur R. J., Zollner H., Chemistry and Biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine 1991 11 1 81 128 2-s2.0-0025814980 10.1016/0891-5849(91)90192-6 (Pubitemid 121003917)
13. Poli G., Schaur R. J., Siems W. G., Leonarduzzi G., 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Medicinal Research Reviews 2008 28 4 569 631 2-s2.0-45249124663 10.1002/med.20117 (Pubitemid 351842143)
14. Petersen D. R., Doorn J. A., Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radical Biology and Medicine 2004 37 7 937 945 2-s2.0-4444314070 10.1016/j.freeradbiomed.2004.06.012 (Pubitemid 39164576)
15. Uchida K., 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Progress in Lipid Research 2003 42 4 318 343 2-s2.0-0037411282 10.1016/S0163-7827(03)00014-6 (Pubitemid 36411689)
16. Grune T., Davies K. J. A., The proteasomal system and HNE-modified proteins. Molecular Aspects of Medicine 2003 24 4-5 195 204 2-s2.0-0041669528 10.1016/S0098-2997(03)00014-1 (Pubitemid 36945019)
17. Dubinina E. E., Dadali V. A., Role of 4-hydroxy-trans-2-nonenal in cell functions. Biochemistry 2010 75 9 1069 1087 2-s2.0-77957742336 10.1134/S0006297910090014
18. Sastry P. S., Lipids of nervous tissue: composition and metabolism. Progress in Lipid Research 1985 24 2 69 176 2-s2.0-0022302720
19. Morrow J. D., Hill K. E., Burk R. F., Nammour T. M., Badr K. F., Roberts L. J. II, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America 1990 87 23 9383 9387 2-s2.0-0025572704 10.1073/pnas.87.23.9383 (Pubitemid 120030630)
20. Morrow J. D., Awad J. A., Boss H. J., Blair I. A., Roberts L. J. II, Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proceedings of the National Academy of Sciences of the United States of America 1992 89 22 10721 10725 2-s2.0-0026443725 10.1073/pnas.89.22. 10721
21. Morrow J. D., Harris T. M., Roberts L. J. II, Noncyclooxygenase oxidative formation of a series of novel prostaglandings: analytical ramifications for measurement of eicosanoids. Analytical Biochemistry 1990 184 1 1 10 2-s2.0-0025058849 10.1016/0003-2697(90)90002-Q (Pubitemid 20029736)
22. Milne G. L., Musiek E. S., Morrow J. D., F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005 10 supplement 1 10 23
23. 4 poisoning? Free Radical Biology and Medicine 2005 38 6 698 710 2-s2.0-13844297589 10.1016/j.freeradbiomed.2004.09. 017 (Pubitemid 40249740)
24. Montuschi P., Barnes P. J., Roberts L. J. II, Isoprostanes: markers and mediators of oxidative stress. FASEB Journal 2004 18 15 1791 1800 2-s2.0-10044235066 10.1096/fj.04-2330rev (Pubitemid 39602265)
25. Basu S., Fatty acid oxidation and isoprostanes: oxidative strain and oxidative stress. Prostaglandins Leukotrienes and Essential Fatty Acids 2010 82 4-6 219 225 2-s2.0-77951975399 10.1016/j.plefa.2010.02.031
26. Basu S., F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxidants and Redox Signaling 2008 10 8 1405 1434 2-s2.0-51749090447 10.1089/ars.2007.1956
27. Halliwell B., Lee C. Y. J., Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxidants and Redox Signaling 2010 13 2 145 156 2-s2.0-77953313356 10.1089/ars.2009.2934
28. Morrow J. D., Zackert W. E., Yang J. P., Kurhts E. H., Callewaert D., Dworski R., Kanai K., Taber D., Moore K., Oates J. A., Roberts L. J., Quantification of the major urinary metabolite of 15-F(2T)-isoprostane (8-iso-PGF(2 α)) by a stable isotope dilution mass spectrometric assay. Analytical Biochemistry 1999 269 2 326 331 2-s2.0-0345211536 10.1006/abio.1999.4008 (Pubitemid 29201031)
29. Roberts L. J. II, Morrow J. D., Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cellular and Molecular Life Sciences 2002 59 5 808 820 2-s2.0-0036286490 10.1007/s00018-002- 8469-8 (Pubitemid 34628242)
30. Morrow J. D., Minton T. A., Mukundan C. R., Campbell M. D., Zackert W. E., Daniel V. C., Badr K. F., Blair I. A., Roberts L. J. II, Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. Journal of Biological Chemistry 1994 269 6 4317 4326 2-s2.0-0027968938
31. Chen Y., Morrow J. D., Roberts L. J. II, Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. Journal of Biological Chemistry 1999 274 16 10863 10868 2-s2.0-0033574541 10.1074/jbc.274.16.10863 (Pubitemid 29191068)
32. Boyland E., Chasseaud L. F., Enzymes catalysing conjugations of glutathione with alpha-beta-unsaturated carbonyl compounds. Biochemical Journal 1968 109 4 651 661 2-s2.0-0014347894
33. 2 Biochemistry 1990 29 15 3760 3765 2-s2.0-0025276249 (Pubitemid 20142719)
34. Milne G. L., Zanoni G., Porta A., Sasi S., Vidari G., Musiek E. S., Freeman M. L., Morrow J. D., The Cyclopentenone Product of Lipid Peroxidation, 15-A 2t-Isoprostane, Is Efficiently Metabolized by HepG2 Cells via Conjugation with Glutathione. Chemical Research in Toxicology 2004 17 1 17 25 2-s2.0-1642579640 10.1021/tx034213o (Pubitemid 38134056)
35. 4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. Journal of Neurochemistry 1999 72 2 734 740 2-s2.0-0032586942 10.1046/j.1471-4159.1999.0720734.x (Pubitemid 29055237)
36. Roberts L. J. II, Montine T. J., Markesbery W. R., Tapper A. R., Hardy P., Chemtob S., Dettbarn W. D., Morrow J. D., Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. Journal of Biological Chemistry 1998 273 22 13605 13612 2-s2.0-0032577553 10.1074/jbc.273.22.13605 (Pubitemid 28268404)
37. Roberts L. J. II, Morrow J. D., Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology and Medicine 2000 28 4 505 513 2-s2.0-0034652768 10.1016/S0891-5849(99)00264-6 (Pubitemid 30136031)
38. Zaja-Milatovic S., Gupta R. C., Aschner M., Montine T. J., Milatovic D., Pharmacologic suppression of oxidative damage and dendritic degeneration following kainic acid-induced excitotoxicity in mouse cerebrum. NeuroToxicology 2008 29 4 621 627 2-s2.0-46149099325 10.1016/j.neuro.2008.04.009
39. Zaja-Milatovic S., Gupta R. C., Aschner M., Milatovic D., Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist. Toxicology and Applied Pharmacology 2009 240 2 124 131 2-s2.0-70349251175 10.1016/j.taap.2009.07.006
40. 4- neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin. Journal of Pineal Research 2009 46 2 148 154 2-s2.0-59149103504 10.1111/j.1600-079X.2008.00639.x
41. 4-neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology 2002 52 2 175 179 2-s2.0-0035984342 10.1002/ana.10272 (Pubitemid 34810597)
42. Montine K. S., Quinn J. F., Zhang J., Fessel J. P., Roberts L. J. II, Morrow J. D., Montine T. J., Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chemistry and Physics of Lipids 2004 128 1-2 117 124 2-s2.0-0842346368 10.1016/j.chemphyslip.2003.10.010 (Pubitemid 38167381)
43. 4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. Journal of Neurochemistry 1999 72 2 734 740 2-s2.0-0032586942 10.1046/j.1471-4159.1999.0720734.x (Pubitemid 29055237)
44. 4-neuroprostanes levels in cerebrospinal fluid with outcome of aneurysmal subarachnoid hemorrhage in humans. Free Radical Biology and Medicine 2009 47 6 814 824 2-s2.0-68549103999 10.1016/j.freeradbiomed.2009.06.026
45. Corcoran T. B., Mas E., Barden A. E., Durand T., Galano J.-M., Roberts L. J., Phillips M., Ho K. M., Mori T. A., Are isofurans and neuroprostanes increased after subarachnoid hemorrhage and traumatic brain injury? Antioxidants and Redox Signaling 2011 15 10 2663 2667 2-s2.0-80054012095 10.1089/ars.2011.4125
46. Quan L. G., Cha J. K., Preparation of isoprostanes and neuroprostanes. Journal of the American Chemical Society 2002 124 42 12424 12425 2-s2.0-0037164005 10.1021/ja027451z (Pubitemid 35204563)
47. Van Rollins M., Woltjer R. L., Yin H., Morrow J. D., Montine T. J., F2-Dihomo-isoprostanes arise from free radical attack on adrenic acid. Journal of Lipid Research 2008 49 5 995 1005 2-s2.0-50049106295 10.1194/jlr.M700503- JLR200
48. De Felice C., Signorini C., Durand T., Oger C., Guy A., Bultel-Poncé V., Galano J.-M., Ciccoli L., Leoncini S., D'Esposito M., Filosa S., Pecorelli A., Valacchi G., Hayek J., F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome. Journal of Lipid Research 2011 52 12 2287 2297 2-s2.0-81855217494 10.1194/jlr.P017798
49. 2 receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochemical Pharmacology 2008 75 12 2301 2315 2-s2.0-44249125696 10.1016/j.bcp.2008.03.014
50. 2 receptors. Journal of Clinical Investigation 1992 90 1 136 141 2-s2.0-0026667087
51. Fukunaga M., Makita N., Roberts L. J. II, Morrow J. D., Takahashi K., Badr K. F., Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. American Journal of Physiology 1993 264 6 C1619 C1624 2-s2.0-0027158234 (Pubitemid 23198533)
52. 2 receptor: a potential link between oxidative stress and impaired angiogenesis. Circulation Research 2008 103 9 1037 1046 2-s2.0-55449120824 10.1161/CIRCRESAHA.108.184036
53. Yura T., Fukunaga M., Khan R., Nassar G. N., Badr K. F., Montero A., Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney International 1999 56 2 471 478 2-s2.0-0032807290 10.1046/j.1523-1755.1999.00596.x (Pubitemid 29353144)
54. Janssen L. J., Isoprostanes: an overview and putative roles in pulmonary pathophysiology. American Journal of Physiology 2001 280 6 L1067 L1082 2-s2.0-0034990522 (Pubitemid 32553245)
55. Montero A., Munger K. A., Khan R. Z., Valdivielso J. M., Morrow J. D., Guasch A., Ziyadeh F. N., Badr K. F., F2-isoprostanes mediate high glucose-induced TGF- β synthesis and glomerular proteinuria in experimental type I diabetes. Kidney International 2000 58 5 1963 1972 2-s2.0-0033736380 10.1046/j.1523-1755.2000.00368.x
56. 3H]D-aspartate release by the 5-F2t-isoprostane and its 5-epimer in isolated bovine retina. Neurochemical Research 2012 37 3 574 582 2-s2.0-80755150244 10.1007/s11064-011-0645-5
57. Basu S., Bioactive eicosanoids: role of prostaglandin F2 α and F2-isoprostanes in inflammation and oxidative stress related pathology. Molecules and Cells 2010 30 5 383 391 2-s2.0-78650476936 10.1007/s10059-010- 0157-1
58. Ting H. J., Khasawneh F. T., Platelet function and Isoprostane biology. Should Isoprostanes be the newest member of the Orphan-ligand family? Journal of Biomedical Science 2010 17 1, article 24 2-s2.0-77950522051 10.1186/1423-0127-17-24
59. Milne G. L., Yin H., Hardy K. D., Davies S. S., Roberts L. J., Isoprostane generation and function. Chemical Reviews 2011 111 10 5973 5996 2-s2.0-80054080478 10.1021/cr200160h
60. Kepp K. P., Bioinorganic chemistry of Alzheimer's disease. Chemical Reviews 2012 112 5193 5239
61. 4 poisoning. Free Radical Biology and Medicine 2005 38 6 711 718 2-s2.0-13844255036 10.1016/j.freeradbiomed.2004.10.024 (Pubitemid 40249741)
62. Jahn U., Galano J.-M., Durand T., Beyond prostaglandins-chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids. Angewandte Chemie 2008 47 32 5894 5955 2-s2.0-51449093769 10.1002/anie.200705122
63. Brooks J. D., Musiek E. S., Koestner T. R., Stankowski J. N., Howard J. R., Brunoldi E. M., Porta A., Zanoni G., Vidari G., Morrow J. D., Milne G. L., McLaughlin B., The fatty acid oxidation product 15-A3t-Isoprostane is a potent inhibitor of NF B transcription and macrophage transformation. Journal of Neurochemistry 2011 119 3 604 616 2-s2.0-80054058222 10.1111/j.1471-4159.2011. 07422.x
64. 2 isoprostane. Journal of Organic Chemistry 2002 67 12 4346 4351 2-s2.0-0037076937 10.1021/jo025652f (Pubitemid 34619845)
65. Hwang S. W., Adiyaman M., Khanapure S., Schio L., Rockach J., Total synthesis of 8-epi-PGF(2 α). A novel strategy for the synthesis of isoprostanes. Journal of the American Chemical Society 1994 116 23 10829 10830 2-s2.0-0027944734 10.1021/ja00102a076 (Pubitemid 24375917)
66. Schrader T. O., Snapper M. L., Stereodivergent synthesis of all 15-F2 isoprostanes. Journal of the American Chemical Society 2002 124 37 10998 11000 2-s2.0-0037130757 10.1021/ja027154u (Pubitemid 35033489)
67. Taber D. F., Reddy P. G., Arneson K. O., A potential route to neuroprostanes and isoprostanes: preparation of the four enantiomerically pure diastereomers of 13- F 4 t -NeuroP. Journal of Organic Chemistry 2008 73 9 3467 3474 2-s2.0-43449102185 10.1021/jo702600v (Pubitemid 351668652)
68. Quan L. G., Cha J. K., Preparation of isoprostanes and neuroprostanes. Journal of the American Chemical Society 2002 124 42 12424 12425 2-s2.0-0037164005 10.1021/ja027451z (Pubitemid 35204563)
69. Oger C., Brinkmann Y., Bouazzaoui S., Durand T., Galano J.-M., Stereocontrolled access to isoprostanes via a bicyclo[3.3.0]octene framework. Organic Letters 2008 10 21 5087 5090 2-s2.0-58149173869 10.1021/ol802104z
70. Oger C., Bultel-Poncé V., Guy A., Durand T., Galano J.-M., Total synthesis of isoprostanes derived from adrenic acid and EPA. European Journal of Organic Chemistry 2012 13 2621 2634 2-s2.0-84860360013 10.1002/ejoc.201200070
71. Rondot B., Durand T., Vidal J.-P., Girard J.-P., Rossi J.-C., Synthesis and determination of cis or trans isoprostane precursors by a 1H NMR NOE study. Journal of the Chemical Society, Perkin Transactions 2 1995 8 1589 1594 2-s2.0-37049075310
72. 1 type I and II. Journal of Organic Chemistry 2005 70 3 989 997 2-s2.0-13244269935 10.1021/jo048179+ (Pubitemid 40189512)
73. Pinot E., Guy A., Fournial A., Balas L., Rossi J.-C., Durand T., Total synthesis of the four enantiomerically pure diasteroisomers of the phytoprostanes E1type II and of the 15-E2t-isoprostanes. Journal of Organic Chemistry 2008 73 8 3063 3069 2-s2.0-42149158973 10.1021/jo702455g (Pubitemid 351543956)
74. 2t-isoprostanes. Journal of Organic Chemistry 2010 75 7 2411 2414 2-s2.0-77950327497 10.1021/jo1000274
75. Le Guennec J.-Y., Galano J.-M., Oger C., Thireau J., Roy J., Bultel-Poncé V., Guy A., Durand T., Methods and pharmaceutical composition for the treatment and prevention of cardiac arrhytmias. European Patent, EP12306519. 3, 2012
76. Galano J.-M., Mas E., Barden A., Mori T. A., Signorini C., De Felice C., Barrett A., Opere C., Pinot E., Schwedhelm E., Benndorf R., Roy J., Le Guennec J. Y., Oger C., Durand T., Isoprostanes and neuroprostanes: Total synthesis, biological activity and biomarkers of oxidative stress in humans. Prostaglandins & Other Lipid Mediators 2013 10.1016/j.prostaglandins.2013.04.003
77. Amir R. E., Van Den Veyver I. B., Wan M., Tran C. Q., Francke U., Zoghbi H. Y., Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl- CpG-binding protein 2. Nature Genetics 1999 23 2 185 188 2-s2.0-0032830639 10.1038/13810 (Pubitemid 29455390)
78. Hagberg B., Aicardi J., Dias K., Ramos O., A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: rett's syndrome. Report of 35 cases. Annals of Neurology 1983 14 4 471 479 2-s2.0-0020507697 (Pubitemid 13010048)
79. Neul J. L., Kaufmann W. E., Glaze D. G., Christodoulou J., Clarke A. J., Bahi-Buisson N., Leonard H., Bailey M. E. S., Schanen N. C., Zappella M., Renieri A., Huppke P., Percy A. K., Rett syndrome: revised diagnostic criteria and nomenclature. Annals of Neurology 2010 68 6 944 950 2-s2.0-78650903501 10.1002/ana.22124
80. Guy J., Cheval H., Selfridge J., Bird A., The role of MeCP2 in the brain. Annual Review of Cell and Developmental Biology 2011 27 631 652 2-s2.0-80054047383 10.1146/annurev-cellbio-092910-154121
81. Derecki N. C., Cronk J. C., Lu Z., Xu E., Abbott S. B. G., Guyenet P. G., Kipnis J., Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012 484 7392 105 109 2-s2.0-84859454582 10.1038/nature10907
82. Chao H.-T., Chen H., Samaco R. C., Xue M., Chahrour M., Yoo J., Neul J. L., Gong S., Lu H.-C., Heintz N., Ekker M., Rubenstein J. L. R., Noebels J. L., Rosenmund C., Zoghbi H. Y., Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010 468 7321 263 269 2-s2.0-78149431869 10.1038/nature09582
83. Grillo E., Lo Rizzo C., Bianciardi L., Bizzarri V., Baldassarri M., Spiga O., Furini S., De Felice C., Signorini C., Leoncini S., Pecorelli A., Ciccoli L., Mencarelli M. A., Hayek J., Meloni I., Ariani F., Mari F., Renieri A., Revealing the complexity of a monogenic disease: rett syndrome exome sequencing. PLoS One 2013 8 2 e56599 10.1371/journal.pone.0056599
84. Pagano G., Castello G., Oxidative stress and mitochondrial dysfunction in down syndrome. Advances in Experimental Medicine and Biology 2012 724 291 299 2-s2.0-84859508314 10.1007/978-1-4614-0653-2-22
85. Chauhan A., Chauhan V., Oxidative stress in autism. Pathophysiology 2006 13 3 171 181 2-s2.0-33745699617 10.1016/j.pathophys.2006.05.007
86. Meguid N. A., Dardir A. A., Abdel-Raouf E. R., Hashish A., Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biological Trace Element Research 2011 143 1 58 65 2-s2.0-80054773490 10.1007/s12011-010-8840-9
87. Sierra C., Vilaseca M. A., Brandi N., Artuch R., Mira A., Nieto M., Pineda M., Oxidative stress in Rett syndrome. Brain and Development 2001 23 1 S236 S239 2-s2.0-0035204275 10.1016/S0387-7604(01)00369-2 (Pubitemid 33111062)
88. De Felice C., Ciccoli L., Leoncini S., Signorini C., Rossi M., Vannuccini L., Guazzi G., Latini G., Comporti M., Valacchi G., Hayek J., Systemic oxidative stress in classic Rett syndrome. Free Radical Biology and Medicine 2009 47 4 440 448 2-s2.0-67649850376 10.1016/j.freeradbiomed.2009.05.016
89. Leoncini S., de Felice C., Signorini C., Pecorelli A., Durand T., Valacchi G., Ciccoli L., Hayek J., Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Report 2011 16 4 145 153 2-s2.0-80052009849 10.1179/1351000211Y.0000000004
90. 4-neuroprostanes mediate neurological severity in Rett syndrome. Clinica Chimica Acta 2011 412 15-16 1399 1406 2-s2.0-79956316620 10.1016/j.cca.2011.04.016
91. Ciccoli L., De Felice C., Paccagnini E., Leoncini S., Pecorelli A., Signorini C., Belmonte G., Valacchi G., Rossi M., Hayek J., Morphological changes and oxidative damage in Rett Syndrome erythrocytes. Biochimica et Biophysica Acta 2012 1820 4 511 520 2-s2.0-84857271395 10.1016/j.bbagen.2011.12. 002
92. Pecorelli A., Ciccoli L., Signorini C., Leoncini S., Giardini A., D'Esposito M., Filosa S., Hayek J., De Felice C., Valacchi G., Increased levels of 4HNE-protein plasma adducts in Rett syndrome. Clinical Biochemistry 2011 44 5-6 368 371 2-s2.0-79952765428 10.1016/j.clinbiochem.2011.01.007
93. Al-Yafee Y. A., Al- Ayadhi L. Y., Haq S. H., El-Ansary A. K., Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia. BMC Neurology 2011 11 article 139 2-s2.0-80155137252 10.1186/1471-2377-11-139
94. Bowers K., Li Q., Bressler J., Avramopoulos D., Newschaffer C., Fallin M. D., Glutathione pathway gene variation and risk of autism spectrum disorders. Journal of Neurodevelopmental Disorders 2011 3 2 132 143 2-s2.0-79958038500 10.1007/s11689-011-9077-4
95. Lehman N. L., The ubiquitin proteasome system in neuropathology. Acta Neuropathologica 2009 118 3 329 347 2-s2.0-68349108020 10.1007/s00401-009-0560-x
96. Reed T., Perluigi M., Sultana R., Pierce W. M., Klein J. B., Turner D. M., Coccia R., Markesbery W. R., Butterfield D. A., Redox proteomic identification of 4-Hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiology of Disease 2008 30 1 107 120 2-s2.0-40849120274 10.1016/j.nbd.2007.12.007
97. Perluigi M., Sultana R., Cenini G., Di Domenico F., Memo M., Pierce W. M., Coccia R., Butterfield D. A., Redox proteomics identification of 4-hydroxynonenalmodified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics 2009 3 6 682 693 2-s2.0-70350089195 10.1002/prca.200800161
98. Lucantoni G., Pietraforte D., Matarrese P., Gambardella L., Metere A., Paone G., Li Bianchi E., Straface E., The red blood cell as a biosensor for monitoring oxidative imbalance in chronic obstructive pulmonary disease: an ex vivo and in vitro study. Antioxidants and Redox Signaling 2006 8 7-8 1171 1182 2-s2.0-33746810931 10.1089/ars.2006.8.1171 (Pubitemid 44182416)
99. Minetti M., Leto T. L., Malorni W., Radical generation and alterations of erythrocyte integrity as bioindicators of diagnostic or prognostic value in COPD? Antioxidants and Redox Signaling 2008 10 4 829 836 2-s2.0-38949161959 10.1089/ars.2007.1864 (Pubitemid 351225894)
100. De Felice C., Signorini C., Durand T., Ciccoli L., Leoncini S., D'Esposito M., Filosa S., Oger C., Guy A., Bultel-Poncé V., Galano J.-M., Pecorelli A., De Felice L., Valacchi G., Hayek J., Partial rescue of Rett syndrome by ω -3 polyunsaturated fatty acids (PUFAs) oil. Genes and Nutrition 2012 7 3 447 458 2-s2.0-84857734934 10.1007/s12263-012-0285-7